It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Cosentyx grew 28% with significant momentum in new indications, Kesimpta expanded by 56% (adjusted), and Kisqali’s U.S. sales ...

From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...

Novartis faces headwinds from Kisqali patent ... Following the CMD update, we particularly note Cosentyx, Kisqali, and Kesimpta, where the management targets are significantly ahead of consensus ...